Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201067
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fernández Velasco, José I. | - |
dc.contributor.author | Monreal, Enric | - |
dc.contributor.author | Kuhle, Jens | - |
dc.contributor.author | Meca Lallana, Virginia | - |
dc.contributor.author | Meca Lallana, José E. | - |
dc.contributor.author | Izquierdo, Guillermo | - |
dc.contributor.author | Oreja Guevara, Celia | - |
dc.contributor.author | Gascón Gimenez, Francisco | - |
dc.contributor.author | Sainz de la Maza, Susana | - |
dc.contributor.author | Walo Delgado, Paulette E. | - |
dc.contributor.author | Lapuente Suanzes, Paloma | - |
dc.contributor.author | Maceski, Aleksandra | - |
dc.contributor.author | Rodriguez Martín, Eulalia | - |
dc.contributor.author | Roldán, Ernesto | - |
dc.contributor.author | Villarrubia, Noelia | - |
dc.contributor.author | Saiz Hinarejos, Albert | - |
dc.contributor.author | Blanco, Yolanda | - |
dc.contributor.author | Diaz Pérez, Carolina | - |
dc.contributor.author | Valero López, Gabriel | - |
dc.contributor.author | Díaz Díaz, Judit | - |
dc.contributor.author | Aladro, Yolanda | - |
dc.contributor.author | Brieva, Luis | - |
dc.contributor.author | Iñíguez, Cristina | - |
dc.contributor.author | González Suárez, Inés | - |
dc.contributor.author | Rodríguez de Antonio, Luis A. | - |
dc.contributor.author | García Domínguez, José M. | - |
dc.contributor.author | Sabin, Julia | - |
dc.contributor.author | Llufriu Duran, Sara | - |
dc.contributor.author | Masjuan, Jaime | - |
dc.contributor.author | Costa Frossard, Lucienne | - |
dc.contributor.author | Villar, Luisa M. | - |
dc.date.accessioned | 2023-07-24T12:25:49Z | - |
dc.date.available | 2023-07-24T12:25:49Z | - |
dc.date.issued | 2022-03-21 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201067 | - |
dc.description.abstract | To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.Copyright © 2022 Fernández-Velasco, Monreal, Kuhle, Meca-Lallana, Meca-Lallana, Izquierdo, Oreja-Guevara, Gascón-Giménez, Sainz de la Maza, Walo-Delgado, Lapuente-Suanzes, Maceski, Rodríguez-Martín, Roldán, Villarrubia, Saiz, Blanco, Diaz-Pérez, Valero-López, Diaz-Diaz, Aladro, Brieva, Íñiguez, González-Suárez, Rodríguez de Antonio, García-Domínguez, Sabin, Llufriu, Masjuan, Costa-Frossard and Villar. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.842354 | - |
dc.relation.ispartof | Frontiers In Immunology, 2022, vol. 13 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2022.842354 | - |
dc.rights | cc by (c) Fernández Velasco, José I. et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Esclerosi múltiple | - |
dc.subject.classification | Imatges per ressonància magnètica | - |
dc.subject.other | Multiple sclerosis | - |
dc.subject.other | Magnetic resonance imaging | - |
dc.title | Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-19T09:42:57Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9306915 | - |
dc.identifier.pmid | 35386690 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved_FrontiersInImmunology.pdf | 1.63 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License